title: Effect of somatostatin analogue octreotide in medulloblastoma in xenograft and cell culture study.
abstract: BACKGROUND
  The effect and possible timing of nonradiolabeled somatostatin analogue octreotide are still not determined in the treatment of medulloblastoma, while the presence of somatostatin receptor type-2 (SSTR2) is proved in the majority of medulloblastoma by several authors.
  
  
  METHODS
  Daoy, SSTR2A positive medulloblastoma cell culture was tested with octreotide in monotherapy and combined with cisplatin, etoposide, and vincristine. Daoy medulloblastoma mice xenograft was treated with octreotide alone.
  
  
  RESULTS
  In monolayer cell culture high-dose octreotide (44 microM) resulted in mitotic inhibition with parallel increment of apoptosis. Combination with cytostatic drugs did not result in additive or synergistic effect, but vincristine was partially antagonized. In medulloblastoma xenograft, octreotide monotherapy (100 microg/kg/day for 10 days) resulted in partial tumor growth inhibition.
  
  
  CONCLUSIONS
  High concentration of nonradiolabeled octreotide may have role in the treatment of medulloblastoma by long-term administration. Concomitant administration of octreotide with widely used cytostatic drugs against medulloblastoma will not have beneficial impact.
authors: 2nd Department of Pediatrics, Semmelweis University, Budapest, Hungary. haupet@gyer2.sote.hu
authors: Péter
authors: P
authors: Hauser
authors: Zoltán
authors: Z
authors: Hanzély
authors: Domokos
authors: D
authors: Máthé
authors: Erika
authors: E
authors: Szabó
authors: Gábor
authors: G
authors: Barna
authors: Anna
authors: A
authors: Sebestyén
authors: András
authors: A
authors: Jeney
authors: Dezso
authors: D
authors: Schuler
authors: György
authors: G
authors: Fekete
authors: Miklós
authors: M
authors: Garami
mesh_terms: D000818:Animals; D018931:Antineoplastic Agents, Hormonal / Q000494:pharmacology / Q000627:therapeutic use*; D000972:Antineoplastic Agents, Phytogenic / Q000494:pharmacology / Q000627:therapeutic use; D017209:Apoptosis; D045744:Cell Line, Tumor; D002528:Cerebellar Neoplasms / Q000188:drug therapy* / Q000473:pathology; D002945:Cisplatin / Q000494:pharmacology / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005047:Etoposide / Q000494:pharmacology / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008527:Medulloblastoma / Q000188:drug therapy* / Q000473:pathology; D051379:Mice; D016513:Mice, SCID; D015282:Octreotide / Q000494:pharmacology / Q000627:therapeutic use*; D017481:Receptors, Somatostatin / Q000378:metabolism*; D014750:Vincristine / Q000494:pharmacology / Q000627:therapeutic use; D023041:Xenograft Model Antitumor Assays
chemical_list: D018931:Antineoplastic Agents, Hormonal; D000972:Antineoplastic Agents, Phytogenic; D017481:Receptors, Somatostatin; D014750:Vincristine; D005047:Etoposide; C093733:somatostatin receptor 2; D002945:Cisplatin; D015282:Octreotide